Perna et al. performed a high-throughput proteomic and transcriptomic analysis to generate an AML surface protein dataset, and evaluated potential target pairs, identifying four combinations (CD33/ADGRE2; CLL-1/CCR1; CD33/CD70; and CLL-1/LILRB2) for future use in preclinical models [21]. This evidence concerns the gene CD33 and acute myeloid leukemia.